You are here

HASTALIKLARIN PATOGENEZ VE TEDAVİSİNDE REAKTİF OKSİJEN PARTİKÜLLERİ VE ANTİOKSİDANLAR

REACTIVE OXYGEN PARTICLES AND ANTIOXIDANTS IN THE PATHOGENESIS AND TREATMENT OF DISEASES

Journal Name:

Publication Year:

Abstract (2. Language): 
Reactive oxygen particles can increase tissue injury in the pathogenesis of human diseases. However, some antioxidants are used for therapeutic approach. In this review, the possible roles of reactive oxygen particles in human diseases and antioxidant drugs in clinical use will be discussed.
Abstract (Original Language): 
Reaktif oksijen partikülleri çoğu hastalıkların primer sebebi olmasalar da patogenezlerinde rol oynayabilir ve doku hasarını arttırabilirler. Bununla birlikte antioksidanlar ise klinik kullanıma girmiştir. Bu makalede reaktif oksijen partiküllerinin çeşitli hastalıkların patogenezindeki rolleri ve antioksidanların klinik kullanımları konusunda genel bir değerlendirme yapılacaktır.
FULL TEXT (PDF): 
96-101

REFERENCES

References: 

1. Carroll E. Cross. Oxygen radicals and human disease. Ann Intern Med 1987; 107: 526 - 545.
2. Southorn P. Free radicals in medicine II. Involvement in human disease. Mayo Clin Proc 1988; 63: 390 - 408.
3. Regnström J, Nilsson J, Tornvall P et al. Susceptibility to low - density lipoprotein oxidation and coronary atherosclerosis in man. The Lancet 1992;339:1183-1186.
4. Steinberg D. Antioxidants and atherosclerosis. Circulation 1991; 84: 1420 - 1425.
5. Parthasarathy S, Wieland E, Steinberg D. Low density protein enriched in oleic acid is protected against oxidative modification: Implications for dietary prevention of atherosclerosis. Proc Natl Acad Sci USA
1990; 87: 3894 - 3898.
6-. Lawrence J. Free radical tissue damage: protective role of
antioxidant nutrients. FASEB J. 1987; 1: 441 - 445.
7. Repine J. Oxidant - antioxidant balance: Some observations from studies of ischemia - reperfusion in isolated perfused rat hearts. Am J Med 1991; 91: 30-45S.
8. Opie L. Myocardial ischemia - Metabolic pathways and implications of increased glycolysis. Cardiovasc Drugs Ther 1990; 4:777 - 790.
9. Wang Q, Giri SN, Hyde DM et al. Niacin attenuates bleomycin - induced lung fibrosis in the hamster. J Biochem Toxicol 1990; 5: 13 - 22.
10. Halliwell B. Reactive oxygen species in living system: source, biochemistry and role in human disease. Am J
Med 1991; 91: 14S-21S.
11. Akaike T, Ando M, Oda T et al. Dependence on 02-generation by xanthine oxidase of pathogenesis of influenza virus infection in mice. J Clin Invest 1990; 85:
739 - 745.
12. Grisham M. Oxidants and free radicals in inflammatory
bowel disease. The Lancet 1994; 344 Sep 24: 859-861.
13. Cerutti P. Oxy - radicals and cancer. The Lancet 1994;
344 Sep. 24: 862-863.
14. Greenberg ER., Baron J, Tosteson T et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. N Engl J Med 1994; 331: 141-147.
15. Heinonen OP, Huttunen JK, Albanes D et al. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med
1994; 330: 1029- 1035.
16. Halliwell B. Oxidants and the central nervous system: some fundamental questions. Acta Neurol Scand 1989;
126:23-33.
17. Nath AK, Fischereder M and Hostetter H. The role of oxidants in progressive renal injury. Kidney Int 1994; 45
(Suppl 45 ): S-lll-S-115.
18. Ichikawa et al. Renal antioxidant enzymes. Kidney Int
1994; 45: 1 -9.
19. Kuroda M, Asaka S, Tofuku Y et al. Serum antioxidant activity in uremic patients. Nephron 1985; 41: 293-298.
20. Breyer J,Hunsicker GL, Bain P.R et al. Angiotensin converting enzyme inhibition in diabetic nephropathy.
Kidney Int 1994; 45 (Suppl 45 ): S-156 - S-160.
21. Lois J, Graham E, Soraya A et al. Effect of sustained pharmacologic vitamin E levels on incidence and severity of retinopathy of prematurity: A controlled
clinical trial. J Pediatr 1989; 114: 827 - 838.
22. Henderson W. The role of leukotriens in inflammation.
100
Ann Intern Med 1994; 121: 684 - 697.
23. Natanson C. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994; 120 (9 ): 771 - 778.
24. Halliwell B', Hoult JRS, Blake DR. Oxidants, inflammation and anti - inflamatory drugs. FASEB Journal 1988; 2: 501 -514.
25. Petch MC. Dangers of thrombolysis. British Medical
Journal 1990; 300: 483.
26. Voest E, Vreugdenhil G, Marx M. Iron - chelating agents in non - iron overload conditions. Ann Intern Med 1994;
120:490-499.
27. Harpey C, Clauser P, Labrid C et al. Trimetazidine, a cellular anti-ischemic agent. Cardiovasc Drug Rev 1988;
6(4): 292-312.
28. Cynamon H, Milov D, Valenstein E et al. Effect of vitamin E deficiency on neurologic function in patients
with cystic fibrosis. J Pediatr 1988; 113: 637-640.
29. Phillips G, Tangney CC. Relationship of plasma alpha tocopherol to index of clinical severity in individuals with sickle cell anemia. Am J Hematol 1992; 11 (4 ): 227-231.
30. Harris WS. The prevention of atherosclerosis with antioxidants. Clin Cardiol 1992; 15 (9): 636 - 640.
31. Van Antwerpen L, Theron A J, Myer MS et al. Cigarette
smoke-mediated oxidant stress, phagocytes, vitamin C, vitamin E, and tissue injury. Ann N Y Acad Sci
1993;28:53-65.
32. Kenneth L. Role of free radicals in lung injury. Chest 1986; 89 (6): 859-863.
33. Ginter E. A new concept of atherogenesis: the role of
oxygen radicals. Vnitr Lek 1992; 38 (11): 1096-1104.
34. Bocan TM, Mueller SB, Brown EQ. Antiatherosclerotic effects of antioxidants are lesion- spesific when evaluated in hypercholesterolemic New Zealand white rabbits. Exp Mol Pathol 1992; 57 (1): 70 - 83.

Thank you for copying data from http://www.arastirmax.com